SlideShare a Scribd company logo
Process Driven Research: A Mild
Version of Grignard Reagents
and Its Applications
Li Zhang
Chemical Development
Boehringer Ingelheim Pharmaceuticals, Inc.
Material
WasteCost

More Related Content

Viewers also liked

From 1 g to market flyer
From 1 g to market flyerFrom 1 g to market flyer
From 1 g to market flyer
Li Zhang
 
Jardiance- PresentationCopy
Jardiance- PresentationCopyJardiance- PresentationCopy
Jardiance- PresentationCopy
dannbetts
 
Cv safety of gliptins
Cv safety of gliptinsCv safety of gliptins
Cv safety of gliptins
DrNeerajB
 
Journal Club March 2010
Journal Club  March 2010Journal Club  March 2010
Journal Club March 2010
Tejas Desai
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
PHAM HUU THAI
 
Evaluation of anticancer agents final
Evaluation of anticancer agents finalEvaluation of anticancer agents final
Evaluation of anticancer agents final
Dr.Anup Thorat
 

Viewers also liked (20)

Vildagliptin
Vildagliptin Vildagliptin
Vildagliptin
 
Degludec insulin journal review
Degludec insulin journal reviewDegludec insulin journal review
Degludec insulin journal review
 
From 1 g to market flyer
From 1 g to market flyerFrom 1 g to market flyer
From 1 g to market flyer
 
Glycemic Control & CV outcome study by lars bryden
Glycemic Control & CV outcome study by lars brydenGlycemic Control & CV outcome study by lars bryden
Glycemic Control & CV outcome study by lars bryden
 
CHINTAN.PPT
CHINTAN.PPTCHINTAN.PPT
CHINTAN.PPT
 
WATCHMAN TRIAL
WATCHMAN TRIALWATCHMAN TRIAL
WATCHMAN TRIAL
 
Jardiance- PresentationCopy
Jardiance- PresentationCopyJardiance- PresentationCopy
Jardiance- PresentationCopy
 
Presentation1 final
Presentation1 finalPresentation1 final
Presentation1 final
 
Cv safety of gliptins
Cv safety of gliptinsCv safety of gliptins
Cv safety of gliptins
 
Journal Club March 2010
Journal Club  March 2010Journal Club  March 2010
Journal Club March 2010
 
Dapagliflozin- a novel SGLT2 inhibitor
Dapagliflozin- a novel SGLT2 inhibitorDapagliflozin- a novel SGLT2 inhibitor
Dapagliflozin- a novel SGLT2 inhibitor
 
Invitro antidiabetic activity
Invitro antidiabetic activityInvitro antidiabetic activity
Invitro antidiabetic activity
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
 
Paradigm hf-trial-ppt-pptx - copia
Paradigm hf-trial-ppt-pptx - copiaParadigm hf-trial-ppt-pptx - copia
Paradigm hf-trial-ppt-pptx - copia
 
Journal club 20 10-2016
Journal club 20 10-2016Journal club 20 10-2016
Journal club 20 10-2016
 
Journal club presentation, Dr Usama Ragab
Journal club presentation, Dr Usama RagabJournal club presentation, Dr Usama Ragab
Journal club presentation, Dr Usama Ragab
 
Evaluation of anticancer agents final
Evaluation of anticancer agents finalEvaluation of anticancer agents final
Evaluation of anticancer agents final
 
DPP4 Inhibitors P4 Seminar2
DPP4 Inhibitors P4 Seminar2DPP4 Inhibitors P4 Seminar2
DPP4 Inhibitors P4 Seminar2
 
Metformin A Pharmacological Preespective
Metformin A Pharmacological PreespectiveMetformin A Pharmacological Preespective
Metformin A Pharmacological Preespective
 
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
Bioabsorbable Drug-Eluting Cardiac Stent AnalysisBioabsorbable Drug-Eluting Cardiac Stent Analysis
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
 

process driven research Mild Grignard 011017 flyer

  • 1. Process Driven Research: A Mild Version of Grignard Reagents and Its Applications Li Zhang Chemical Development Boehringer Ingelheim Pharmaceuticals, Inc. Material WasteCost